Recent analyst upgrades and downgrades have been making an impact on Wall Street, with numerous firms adjusting their outlook on various companies. Gilead Sciences (GILD) received an upgrade from Cantor Fitzgerald, which raised its rating to Overweight from Neutral and increased its price target to $125 from $100. This upgrade reflects optimism about the clinical progress and market potential of lenacapavir and Biktarvy, with anticipated growth in Gilead's HIV franchise potentially driving margin expansion from 2025 to 2030.
In other notable moves, Regeneron Pharmaceuticals (REGN) was also upgraded by Cantor Fitzgerald to Overweight with a revised price target of $695, adjusted downward from $800. The firm cited pricing concerns and challenges with Eylea and Dupixent as factors previously impacting valuations.
Meanwhile, Sportradar (SRAD) caught the attention of BofA, which double upgraded the stock to Buy from Underperform, raising the price target to $28. The bank highlighted improved cost visibility and revenue outlook as key factors for its enhanced confidence in Sportradar's future performance.
In the storage sector, BofA upgraded Extra Space Storage (EXR) to Neutral, increasing its target price to $155. The firm's optimism stems from the company's rebranding initiatives and expected cost savings. Similarly, Public Storage (PSA) received an upgrade to Buy, supported by its strong financial position, which is seen as a buffer against potential economic downturns.
Conversely, Texas Instruments (TXN) was downgraded by Barclays to Underweight due to concerns over its China supply chain and auto sector exposure, resulting in a lowered price target of $125 from $180. Additionally, UnitedHealth (UNH) and UPS (UPS) experienced downgrades amidst concerns over cost trends and operational challenges.
Initiations of note include Huatai Securities' coverage of Apple (AAPL, Financial) with a Buy rating and a $254 price target, reflecting the tech giant's strong foothold in the premium hardware market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 43 analysts, the average target price for Apple Inc (AAPL, Financial) is $237.71 with a high estimate of $300.00 and a low estimate of $141.00. The average target implies an upside of 20.25% from the current price of $197.69. More detailed estimate data can be found on the Apple Inc (AAPL) Forecast page.
Based on the consensus recommendation from 49 brokerage firms, Apple Inc's (AAPL, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apple Inc (AAPL, Financial) in one year is $206.34, suggesting a upside of 4.38% from the current price of $197.685. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apple Inc (AAPL) Summary page.
